The discovery of mutations in the epidermal growth factor receptor (EGFR), as well as that of EGFR-tyrosine kinase inhibitors (TKIs), introduced a new era of precision medicine in lung cancer treatment1,2. This evidence concerns the gene EGFR and lung carcinoma.